Catalog No.
RVV31401
Species reactivity
Zika virus (ZIKV), Dengue virus 1, Dengue virus type 1 (strain Nauru/West Pac/1974) (DENV-1)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Genome polyprotein, Envelope protein E
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q32ZE1, A0A192GPS0, Q8BE39, P17763
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Z004
Structural basis for antibody cross-neutralization of dengue and Zika viruses., PMID:40502094
A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage., PMID:40425591
Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage., PMID:40013767
A Lambda-evo (λevo) phage platform for Zika virus EDIII protein display., PMID:39820667
ITGB4/CD104 mediates zika virus attachment and infection., PMID:39737945
Serotype-Specific Dengue Virus IgG Assay Using EDIII-Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil., PMID:39620308
Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus., PMID:39547049
A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice., PMID:39414822
Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines., PMID:39340083
Predicting immune response targets in orthoflaviviruses through sequence homology and computational analysis., PMID:39083139
[Preparation of monoclonal antibodies against the envelope protein extracellular domain of Zika virus in mice]., PMID:38790101
A Host Receptor Nanodisc-Based Biosensor Platform for the Detection of a Specific Virus and Its Variants., PMID:38668735
Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8+T cells., PMID:38643856
Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein., PMID:38574259
Multiplex Serology for Sensitive and Specific Flavivirus IgG Detection: Addition of Envelope Protein Domain III to NS1 Increases Sensitivity for Tick-Borne Encephalitis Virus IgG Detection., PMID:38400061
Bovine serum albumin nanoparticles containing Poly (I:C) can enhance the neutralizing antibody response induced by envelope protein of Orthoflavivirus zikaense., PMID:38219440
Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection., PMID:38035335
Recombinant TBEV Protein E of the Siberian Subtype Is a Candidate Antigen in the ELISA Test System for Differential Diagnosis., PMID:37892100
The 3' terminal region of Zika virus RNA contains a conserved G-quadruplex and is unfolded by human DDX17., PMID:37774422
Recombinant protein based on domain III and capsid regions of zika virus induces humoral and cellular immune response in immunocompetent BALB/c mice., PMID:37599141
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement., PMID:37316861
A Ferritin Nanoparticle-Based Zika Virus Vaccine Candidate Induces Robust Humoral and Cellular Immune Responses and Protects Mice from Lethal Virus Challenge., PMID:37112733
Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells., PMID:37006270
Antibody cross-reactivity and evidence of susceptibility to emerging Flaviviruses in the dengue-endemic Brazilian Amazon., PMID:36736575
Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients., PMID:36668962
Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice., PMID:36471432
A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization., PMID:36402135
Evaluation of Zika virus DNA vaccines based on NS1 and domain III of E., PMID:36274487
ZIKV-envelope proteins induce specific humoral and cellular immunity in distinct mice strains., PMID:36131132
Efficient Gene Transfer to Kidney Using a Lentiviral Vector Pseudotyped with Zika Virus Envelope Glycoprotein., PMID:35904396
New Anti-Flavivirus Fusion Loop Human Antibodies with Zika Virus-Neutralizing Potential., PMID:35887153
Can Modern Molecular Modeling Methods Help Find the Area of Potential Vulnerability of Flaviviruses?, PMID:35887069
Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges., PMID:35631599
Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function., PMID:35575481
Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo., PMID:35231399
Development of a neutralizing antibody targeting linear epitope of the envelope protein domain III of ZIKV., PMID:34678322
Conjugation of Zika virus EDIII with CRM197, 8-arm PEG and mannan for development of an effective Zika virus vaccine., PMID:34474053
Identifying crucial E-protein residues responsible for unusual stability of Zika virus envelope., PMID:34390684
An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens., PMID:34086672
Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning., PMID:33929789
Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene., PMID:33913804
Optimization of Zika DNA vaccine by delivery systems., PMID:33780719
Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation., PMID:33746970
A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies., PMID:33597214
Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody., PMID:33535104
Conjugation of Hemoglobin and Mannan Markedly Improves the Immunogenicity of Domain III of the Zika Virus E Protein: Structural and Immunological Study., PMID:33522239
Multiplex detection of antibodies to Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-human primate species from Cameroon and the Democratic Republic of Congo., PMID:33476338
A functional interaction between GRP78 and Zika virus E protein., PMID:33432092
Immune Reactivity of a 20-mer Peptide Representing the Zika E Glycan Loop Involves the Antigenic Determinants E-152/156/158., PMID:33167511
Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy., PMID:33077712
For research use only. Not for human or drug use.
